Recommended Dosage in

IMFINZI is given as a fixed 1500mg dose for the first-line treatment of ES-SCLC1



  • IMFINZI 1500-mg fixed dose
    fixed dose

  • IV bag icon

  • IV bag icon



  • IMFINZI 1500-mg fixed dose
    fixed dose

  • until disease progression or
    unacceptable toxicity

Patients with a body weight of ≤30 kg must receive weight-based dosing, equivalent to IMFINZI 20 mg/kg according to the same dosing schedule as above. IMFINZI may be given as 1500mg fixed dose once body weight increases to >30 kg.1

EP consists of etoposide 80 mg/m2 to 100 mg/m2 with either carboplatin AUC 5 mg/mL/min or 6 mg/mL/min or cisplatin 75 mg/m2 to 80 mg/m2. For more information, please refer to the Prescribing Information for each treatment.1

  • IMFINZI is administered as a 60-minute IV infusion1
  • No premedication is required for IMFINZI treatment1
  • Administer IMFINZI prior to chemotherapy on the same day1

Administer IMFINZI + EP every 3 weeks for 4 cycles followed by monthly maintenance with IMFINZI1

ES-SCLC=extensive-stage small cell lung cancer; Q3W=once every 3 weeks; Q4W=once every 4 weeks; EP=etoposide and either carboplatin or cisplatin; AUC=area under the curve; IV=intravenous.


Dosage Modifications in

Dosage reduction of IMFINZI is not recommended1

Withhold iconWITHHOLD


IMFINZI for any of the following1:

  • Pneumonitis: Grade 2
  • Hepatitis:For grade 2 with ALT/AST > 3 to 5 x ULN and/or total bilirubin >1.5 to 3 x ULN
    or grade 3 with AST/ALT >5 to ≤ 8 x ULN or total bilirubin > 3 to ≤ 5 x ULN
  • Colitis or diarrhoea: Grade 2
  • Hyperthyroidisim or thyroiditis, adrenal insufficiency, hypophysitis/hypopituitarism, or type 1 diabetes mellitus: Grades 2-4
  • Nephritis: For grade 2 with serum creatinine > 1.5 to 3 x (ULN or baseline)
  • Rash or dermatitis: Grade 2 for >1 week or Grade 3
  • Infection: Grade 3 or 4
  • Myocarditis: Grade 2
  • Myositis/polymyositis: Grade 2 or 3
  • Other immune-mediated adverse reactions: Grade 3*



IMFINZI may be resumed within 12 weeks before in patients
whose adverse reactions recover to Grade ≤1 and have prednisone dose reduced to ≤10 mg/day (or equivalent)



IMFINZI for any of the following1:

  • Pneumonitis: Grade 3 or 4
  • Hepatitis: For Grade 3 with ALT/AST > 8 x ULN or total bilirubin >5 x ULN
    concurrent AST/ALT >3 x ULN and total bilirubin >2 x ULN with no other cause
  • Colitis or diarrhoea: Grade 3 or 4
  • Nephritis: For grade 3 with serum creatinine > 3 x baseline
    > 3 to 6 x ULN or grade 4 with serum creatinine > 6 x ULN
  • Rash or dermatitis: Grade 4
  • Infusion-related reactions: Grade 3 or 4
  • Myositis/polymyositis: Grade 4
  • Other immune-mediated adverse reactions: Grade 4
  • Persistent Grade 2 or 3 adverse reactions (excluding endocrinopathies) that do not recover to Grade 0 or 1 within 12 weeks after the last IMFINZI dose
  • Inability to taper corticosteroid to prednisone ≤10 mg per day (or equivalent) within 12 weeks after the last IMFINZI dose
  • Recurrent Grade 3 or 4 (severe or life-threatening) adverse reactions
  • infusion-related reactions: Grade 1 or 2 interrupt or slow the rate of infusion. May consider pre-medications for prophylaxis of subsequent infusion reactions.
Prescribing Information has additional information for dosage modification and management specific to adverse reactions.

ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal.

*For myasthenia gravis, permanently discontinue IMFINZI if the adverse reaction does not resolve to ≤Grade 1 within 30 days or if there are signs of respiratory and/or autonomic insufficiency.1

Preparation, Storage, Administration in ES-SCLC


  • Eye icon

    Visually inspect drug product for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard the vial if the solution is cloudy, discolored, or visible particles are observed

  • Do not shake vial icon

    Do not shake the vial

  • Intravenous bag icon

    Withdraw the required volume from the vials of IMFINZI and transfer into an IV bag containing 0.9% Sodium Chloride Injection or 5% Glucose Injection. Mix diluted solution by gentle inversion. Do not shake the solution. The final concentration of the diluted solution should be between 1 mg/mL and 15 mg/mL

  • Disposal icon

    Discard partially used or empty vials of IMFINZI

Storage of infusion solution1

IMFINZI does not contain a preservative.

Administer infusion solution immediately once prepared. If infusion solution is not administered immediately and needs to be stored, the total time from vial puncture to the start of the administration should not exceed:

  • Refrigerator storage icon

    24 hours in a refrigerator at
    2°C to 8°C 

  • Room temperature icon

    12 hours at room temperature up to

  • Additionally:

  • Do not freeze icon

    Do not freeze

  • Do not shake the IV bag icon

    Do not shake


  • Administration time icon

    Administer infusion solution intravenously over 60 minutes through an IV line containing a sterile, low-protein binding 0.2 or 0.22 micron in-line filter

  • Do not co-administer icon

    Do not co-administer other drugs through the same infusion line

Dosage forms and strengths1

  • Dosage forms and strengths icon

    Injection: 500 mg/10 mL (50 mg/mL) clear to opalescent, colorless to slightly yellow solution in a single-dose vial



Reference: 1. IMFINZI SmPC, September 2020.